Special Report: Acute and Chronic Gout—New Agents Target Refractory Patients and Tap Market OpportunityDecision Resources
October 1, 2010
More Rheumatology/Arthritis reports by Decision Resources
Rheumatoid Arthritis in Brazil, Russia, and China – How Are Payers and Prescribers Promoting or Limiting Growth in the Biologics Markets by Decision Resources
This report is based on a survey of 150 prescribers (rheumatologists) and interviews with 12 payers. Interviewed payers have influence at a national ...
LaunchTrends®: Abatacept SC (Orencia SC) (Wave 4) 2012 by Decision Resources
This report is a series of four post-launch reports that evaluates the trial and usage of ORENCIA SC (abatacept) among rheumatologists for the treatment of ...
How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis? by Decision Resources
The moderate to severe RA population represents a sizable target for agents acting on the immune system. However, the barriers to entry are ...
TreatmentTrends®: Rheumatoid Arthritis (EU) 2012 by Decision ResourcesSee all reports like this >>
TreatmentTrends® Biologics in Rheumatoid Arthritis (EU) is a report that covers the use of biologics for the treatment of RA in the E5 countries. This ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Rheumatoid Arthritis – Pipeline Review, H1 2013
- Rheumatoid Arthritis Partnering 2007-2013
- Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth
- Rheumatoid Arthritis in Brazil, Russia, and China – How Are Payers and Prescribers Promoting or Limiting Growth in the Biologics Markets
- LaunchTrends®: Abatacept SC (Orencia SC) (Wave 4) 2012